Investigation of the ROle of faT and inflAmmaTory cells in mElanoma

  • Research type

    Research Study

  • Full title

    A Clinical, Histological, Cellular and Molecular Investigation of the role of fat and inflammatory cells in melanoma plasticity and metastases.

  • IRAS ID

    357608

  • Contact name

    Deemesh Oudit

  • Contact email

    deemesh.oudit@nhs.net

  • Sponsor organisation

    The Christie NHS Foundation Trust

  • Duration of Study in the UK

    1 years, 0 months, 1 days

  • Research summary

    This study is a retrospective, proof-of-concept sample study to investigate a novel histological finding within the primary melanoma tumour in a large population of melanoma patients to assess its prognostic significance.
    This is a aims to validate the striking observation that a cross-talk between fat cells and leukocytes at the primary melanoma site promotes metastasis.

    In our unpublished pilot study, we have discovered an interesting finding whereby inflammatory cells extend from the tumour to and invading fat in the subcutaneous tissue and/or around the appendageal structures in the dermal skin in metastatic melanomas with distinct architectural changes within the fat. This finding was consistently present in metastatic and absent in non-metastatic melanomas.
    This new finding has both clinical and pathophysiological credence.

    Archival tissue blocks or human cell lines will be used in the first instance. As mitigation, experiments will be repeated with conditioned media obtained from co-culture of mixed primary immune cells obtained from peripheral blood mononuclear cell (PBMCs) and adipocytes induced from stem cells.

    This study aims to:
    - Investigate if the crosstalk between fat cells and tumour-infiltrating inflammatory cells defines the aggressiveness of primary cutaneous melanomas.

    - Identify and perform biological spatial analysis of the inflammatory cells between the tumour and fat in the primary tumours.

    - Investigate the interactions of fat cells and/or inflammatory cells in mediating melanoma cellular plasticity.

    The patients have not provided consent and will be justified in this application.

  • REC name

    London - Stanmore Research Ethics Committee

  • REC reference

    26/PR/0033

  • Date of REC Opinion

    29 Jan 2026

  • REC opinion

    Favourable Opinion